Results 31 to 40 of about 15,616 (165)

Patient‐reported outcomes and medication errors during oral antitumour therapy in paediatrics: Results from the youngAMBORA care programme

British Journal of Clinical Pharmacology, EarlyView.
Aim Increasing use of oral antitumour therapeutics (OAT) in paediatrics is associated with numerous advantages, but also with error‐prone aspects. Based on the randomized AMBORA trial including adults treated with various OAT, we developed a tailored pharmacological/pharmaceutical care programme for children and their caregivers during OAT treatment ...
Phyllis Lensker, Lisa Cuba, Frank Dörje, Martin F. Fromm, Markus Metzler   +4 more
wiley   +1 more source

Efficacy and Safety of Durvalumab and Tremelimumab in Metastatic Non‐Small Cell Lung Cancer: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Chronic Diseases and Translational Medicine, EarlyView.
PRISMA 2020 flow diagram of included studies. ABSTRACT Purpose Immune checkpoint inhibitors have transformed treatment strategies for metastatic non‐small cell lung cancer (mNSCLC). This study aimed to assess the efficacy and safety of durvalumab combined with tremelimumab compared with those of standard chemotherapy, particularly in patients with low ...
Ikhwan Rinaldi, Eric Ricardo Yonatan, Tasia Esterita   +2 more
wiley   +1 more source

Isoform Specificity of a Compound Targeting Actin Filaments Containing Tropomyosin Tpm1.8/1.9

Cytoskeleton, EarlyView.
ABSTRACT The unbranched actin filaments in mammalian cells are usually composed of co‐polymers of a specific tropomyosin isoform with actin. Genetic manipulation has revealed that the tropomyosins largely define the functional properties of actin filaments in an isoform‐specific, non‐redundant manner.
Jeff Hook, Edna C. Hardeman, Peter W. Gunning   +2 more
wiley   +1 more source

Vinorelbine With or Without Thiotepa for HER2‐Negative Metastatic Breast Cancer: A Propensity Score Analysis

Cancer Medicine
Background Vinorelbine is commonly used to treat metastatic breast cancer (mBC), while thiotepa is known for its ability to cross the blood–brain barrier.
Aurelia Robert, Paul Gougis, Elise Dumas, Rebecca Loison, Victoire De Castelbajac, Marc Espie, Sylvie Giacchetti, Caroline Cuvier, Lamia Hassani, Johanna Wassermann, Luca Campedel, Marianne Veyri, Aurore Vozy, Jean Philippe Spano, Luis Teixeira, Baptiste Abbar   +15 more
doaj   +1 more source

Maternal and Neonatal Complications Associated with Breast Cancer Systemic Treatments—A VigiBase Disproportionality Analysis Study

Clinical Pharmacology &Therapeutics, EarlyView.
Pregnancy‐associated breast cancer (PrBC) presents therapeutic challenges. Understanding maternal–fetal safety of systemic anticancer therapies is critical. We performed a case/non‐case disproportionality analysis using the WHO global pharmacovigilance database up to January 2024, to evaluate maternal–fetal outcomes associated with breast cancer (BC ...
Rayan Kabirian, Floriane Jochum, Elise Dumas, Florence Coussy, Kevin Bihan, Bénédicte Lebrun‐Vignes, Barbara Pistilli, Marc‐Antoine Benderra, Lise Selleret, Laurent Chouchana, Fabien Reyal, Anne‐Sophie Hamy, Paul Gougis   +12 more
wiley   +1 more source

The role of autophagy in human lung cancer cell line A549 induced by Vinorelbine

Chinese Journal of Lung Cancer, 2008
Background and objective It has been proven that many kinds of drug could induce autophagy in tumor cells. The aim of the study is to verify whether Vinorelbine could induce autophagy in A549 cell lines, and to investigate the role in the effectiveness ...
Xiao FU, Yongcheng PAN, Jianjun WANG, Quan LIU, Guanghai YANG, Jinsong LI   +5 more
doaj  

Clinical Relevance of BACH1 Expression in Non–Small Cell Lung Cancer

International Journal of Cancer, EarlyView.
ABSTRACT BTB and CNC homolog 1 (BACH1) is a redox‐sensitive transcription factor implicated in tumor progression, metabolic reprogramming, and therapy resistance in several cancers. However, its prognostic significance and role in therapy resistance in non–small cell lung cancer (NSCLC) remain unclear.
Jing Liu, Marc A. Schneider, Julia Held, Sabine Wrenger, Wenzhang Si, Michael Allgaeuer, Florian Eichhorn, Sabina Janciauskiene   +7 more
wiley   +1 more source

Palbociclib in the Treatment of HR+/ HER2‐ Advanced or Metastatic Breast Cancer in Australia: A Real‐World Retrospective Analysis

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This study investigated the real‐world use of CDK4/6 inhibitors in Australian patients with HR+/HER2‐ advanced or metastatic breast cancer, providing data on patient demographics, treatment patterns, and outcomes with palbociclib. ABSTRACT Background There is limited real‐world data on the use of CDK4/6 inhibitors in Australian patients with HR+/HER2 ...
Louise Nott, Eugene Moylan, Maree Colosimo, Giles Stratton, Thomas Chiu, Mahsa H. Kouhkamari, Maureen Hitschfeld, Jessica Michie, Richard De Boer   +8 more
wiley   +1 more source

Comprehensive Genomic Profiling Beyond Driver Testing in Non‐Squamous Non‐Small Cell Lung Cancer With Known Drivers

Cancer Science, EarlyView.
Figure 6 Comprehensive genomic profiling identified additional actionable alterations in a substantial proportion of patients with non‐squamous NSCLC despite previously identified driver alterations, with some findings leading to subsequent matched targeted therapies.
Yoshihiro Masui, Tatsuya Yoshida, Yoh Yamaguchi, Jun Miyakoshi, Ryoko Inaba Higashiyama, Akiko Tateishi, Yuki Shinno, Yuji Matsumoto, Yusuke Okuma, Tomonori Mizutani, Hidehito Horinouchi, Kouya Shiraishi, Takashi Kohno, Takafumi Koyama, Noboru Yamamoto, Yasushi Goto   +15 more
wiley   +1 more source

Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study

Breast
Introduction: Single-agent oral vinorelbine is a standard of care for hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) that has progressed on endocrine therapy. Metronomic administration
Gilles Freyer, Noelia Martinez-Jañez, Bożena Kukielka-Budny, Malgorzata Ulanska, Hugues Bourgeois, Montserrat Muñoz, Serafin Morales, Juan Bayo Calero, Laura Cortesi, Tamás Pintér, Markéta Palácová, Nelli Cherciu, Edgar Petru, Johannes Ettl, Cécilia de Almeida, Gustavo Villanova, Romain Raymond, Christine Ta Thanh Minh, Ana Rodrigues, Marina E. Cazzaniga   +19 more
doaj   +1 more source